Two genomic tests identify groups of patients most likely to benefit from new drugs
New results from a long-running trial to identify which new drugs or combinations of drugs are most effective in which types of breast cancer, show that two genomic tests are bringing the era of truly personalised medicine ever nearer. Professor Laura van ‘t Veer, leader of the Breast Oncology Program at the University of California San Francisco, USA, told the […]
Continue reading »